This collection was purchased jointly with the New England Regional Center of Excellence in Biodefense and Emerging Infectious Diseases (NERCE) and the Laboratory for Drug Discovery for Neurodegeneration (LDDN) in June 2004. Funding was provided by NERCE and the Dana Farber/Harvard Cancer Center (DF/HCC) Cancer Drug Assays program (CDA). With the assistance of Dr. Tudor Oprea at the University of New Mexico, these compounds were specifically chosen to increase the overall diversity of the ICCB collection, and were also selected for favorable physico-chemical properties, such as solubility, decreased toxicity, and increased stability.
Note: Plate #1366 is no longer available for screening (3/1/2016)
| Number of Compounds | 1,700 |
| Plate Numbers | 1364-1368 (4 Plates) |
| Concentration Information | 5 mg/mL in DMSO |
384-Well Plate Format
